We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.15%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$843M
AUM Growth
+$92.2M
Cap. Flow
+$126M
Cap. Flow %
14.96%
Top 10 Hldgs %
33.86%
Holding
109
New
20
Increased
44
Reduced
26
Closed
18

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$21.4M
2
CVS icon
CVS Health
CVS
+$19M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.7M
4
RVTY icon
Revvity
RVTY
+$16.1M
5
UNH icon
UnitedHealth
UNH
+$15.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$27.5M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$20.3M
3
ABT icon
Abbott
ABT
+$20M
4
GILD icon
Gilead Sciences
GILD
+$16.1M
5
BSX icon
Boston Scientific
BSX
+$11.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGEN icon
51
Precigen
PGEN
$2.45B
$4.76M 0.56%
+3,191,343
New +$5.02M
MLYS icon
52
Mineralys Therapeutics
MLYS
$2.38B
$4.67M 0.55%
+293,928
New +$3.38M
FOLD
53
DELISTED
Amicus Therapeutics
FOLD
$4.64M 0.55%
568,952
-215,424
-27% -$1.99M
ATEC icon
54
Alphatec Holdings
ATEC
$1.49B
$4.52M 0.54%
446,106
+217,772
+95% +$2.34M
ACLX
55
DELISTED
Arcellx
ACLX
$4.42M 0.52%
67,390
+22,898
+51% +$1.55M
URGN icon
56
UroGen Pharma
URGN
$2.39B
$4.35M 0.52%
393,153
+23,292
+6% +$248K
NRIX icon
57
Nurix Therapeutics
NRIX
$2.76B
$4.16M 0.49%
350,420
-181,752
-34% -$3.04M
LUNG icon
58
Pulmonx
LUNG
$98.4M
$4.12M 0.49%
611,875
+404,022
+194% +$2.86M
OPRX icon
59
OptimizeRx
OPRX
$132M
$4.11M 0.49%
+475,000
New +$2.9M
GH icon
60
Guardant Health
GH
$22.2B
$3.81M 0.45%
+89,329
New +$3.85M
PCVX icon
61
Vaxcyte
PCVX
$8.88B
$3.53M 0.42%
93,431
-22,707
-20% -$1.82M
SIBN icon
62
SI-BONE Inc
SIBN
$852M
$3.24M 0.38%
231,109
+14,509
+7% +$234K
UTHR icon
63
United Therapeutics
UTHR
$21.9B
$3.15M 0.37%
10,232
-27,240
-73% -$9.34M
NSPR icon
64
InspireMD
NSPR
$40.3M
$3.15M 0.37%
1,171,416
+316,700
+37% +$896K
PHLT
65
DELISTED
Performant Healthcare Inc
PHLT
$3.14M 0.37%
1,060,601
-197,204
-16% -$511K
DVAX
66
DELISTED
Dynavax Technologies
DVAX
$3.05M 0.36%
234,784
+13,804
+6% +$183K
INSM icon
67
Insmed
INSM
$28.9B
$2.89M 0.34%
37,901
+2,233
+6% +$171K
AORT icon
68
Artivion
AORT
$1.4B
$2.74M 0.33%
+111,652
New +$3.1M
TERN
69
DELISTED
Terns Pharmaceuticals
TERN
$2.65M 0.31%
959,703
+130,598
+16% +$533K
OM icon
70
Outset Medical
OM
$84.6M
$2.56M 0.3%
+231,099
New +$2.76M
MBX
71
MBX Biosciences
MBX
$3.23B
$2.42M 0.29%
328,323
+158,323
+93% +$1.67M
KROS icon
72
Keros Therapeutics
KROS
$222M
$2.22M 0.26%
217,753
-96,788
-31% -$1.12M
QURE icon
73
uniQure
QURE
$3.13B
$2.16M 0.26%
203,833
-71,167
-26% -$998K
CRNX icon
74
Crinetics Pharmaceuticals
CRNX
$8.96B
$2.14M 0.25%
63,940
+12,807
+25% +$478K
NAMS icon
75
NewAmsterdam Pharma
NAMS
$3.33B
$2.07M 0.25%
100,955
+24,839
+33% +$552K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Parkman Healthcare Partners held 109 positions worth $843M, up 12% from $751M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Parkman Healthcare Partners deployed $126M of net new capital in Q1 2025, opening 20 new positions and adding to 44 existing holdings. Its largest new stake was Zimmer Biomet: 200,500 shares worth $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $27.5M trimmed.

  • Parkman Healthcare Partners's largest Q1 2025 buy was Zimmer Biomet: 200,500 shares worth $22.7M.
  • Parkman Healthcare Partners added most to CVS Health in Q1 2025, an estimated $19M increase.
  • Parkman Healthcare Partners's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $27.5M.
  • Parkman Healthcare Partners fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $20.3M.
  • Parkman Healthcare Partners's ten largest holdings make up 34% of its $843M portfolio in Q1 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 18 in Q1 2025.
  • Parkman Healthcare Partners's portfolio value rose 12% quarter-over-quarter to $843M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2025, filed 15 May 2025.